Table 1. Inhibitor development from ED 1... | American Society of Hematology

Table 1.

Inhibitor development from ED 1 until 1000 EDs for all and high-titer inhibitors

EDs	Patients at risk	Patients with inhibitors	High-titer inhibitors	All inhibitors, cumulative %
0	1038	0	0	0
1-10	897	109	78	36
11-20	753	236	173	79
21-30	708	268	196	89
31-40	688	282	203	94
41-50	654	289	208	96
51-60	646	294	210	98
61-75	601	298	212	99.3
76-150	568	298	212	99.3
151-250	524	299	212	99.7
251-500	430	300	212	100
501-1000	214	300	212	100

EDs	Patients at risk	Patients with inhibitors	High-titer inhibitors	All inhibitors, cumulative %
0	1038	0	0	0
1-10	897	109	78	36
11-20	753	236	173	79
21-30	708	268	196	89
31-40	688	282	203	94
41-50	654	289	208	96
51-60	646	294	210	98
61-75	601	298	212	99.3
76-150	568	298	212	99.3
151-250	524	299	212	99.7
251-500	430	300	212	100
501-1000	214	300	212	100

The cumulative inhibitor incidence for all inhibitors is reported during follow-up.